Scarica l'app Stockscreener
2.065
0.51%
-0.015
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VTYX Giù?
Forum
Previsione
Ventyx Biosciences Inc Borsa (VTYX) Ultime notizie
Ventyx stock steady as Parkinson’s drug shows biomarker reductions By Investing.com - Investing.com India
Ventyx reports positive outcomes from trial of VTX3232 for Parkinson’s - Yahoo Finance
Ventyx Biosciences Inc’s Mixed Bag: Down -9.22% in 6 Months, Down 58.21% in 30 Days - investchronicle.com
Ventyx Biosciences Announces Positive Top-Line Data from - GlobeNewswire
Ventyx Biosciences Shares Fall After Tier 2 Exploratory Biomarkers Remain Stable in Parkinson's Study - MarketScreener
Ventyx reports positive Phase 2a results for Parkinson’s drug - Investing.com
Ventyx Biosciences Insiders Placed Bullish Bets Worth US$1.26m - Yahoo
Ventyx Biosciences' Study of VTX3232 Met Safety, Tolerability Objectives - MarketWatch
Ventyx posts mid-stage trial win for Parkinson’s drug (VTYX) - Seeking Alpha
Ventyx Biosciences stock trades flat despite positive parkinson’s drug trial data - Investing.com Canada
Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson'S Disease - marketscreener.com
Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson’S Disease - TradingView
Ventyx reports positive Phase 2a results for Parkinson’s drug By Investing.com - Investing.com India
VTYX Trading Halted as Market Awaits News Update | VTYX Stock News - GuruFocus
Piper Sandler maintains $21 target on Ventyx stock By Investing.com - Investing.com Nigeria
Traders Buy Large Volume of Ventyx Biosciences Call Options (NASDAQ:VTYX) - Defense World
Ventyx Biosciences reports annual meeting results By Investing.com - Investing.com South Africa
Ventyx Biosciences reports annual meeting results - Investing.com
Piper Sandler maintains $21 target on Ventyx stock - Investing.com
As Ventyx Approaches Multiple Phase II Readouts, What Could Be Next For The Stock? - RTTNews
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Squarepoint Ops LLC - Defense World
Two Sigma Investments LP Has $1.04 Million Stock Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences at Jefferies Conference: Strategic Developments in Focus By Investing.com - Investing.com Canada
Millennium Management LLC Purchases 1,008,760 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by D. E. Shaw & Co. Inc. - Defense World
Northern Trust Corp Buys 19,982 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Ventyx Biosciences Executives Set for Key Presentation on Autoimmune Drug Pipeline at Jefferies Conference - Stock Titan
BNP Paribas Financial Markets Takes Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Bank of America Corp DE Has $9.36 Million Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Pre-market Movers: VIGL, CVM, KDLY, VTAK... - RTTNews
Spotlight On 3 Penny Stocks With Market Caps Under $500M - simplywall.st
VTYX LAWSUIT ALERT: Levi & Korsinsky Notifies Ventyx Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Price T Rowe Associates Inc. MD Sells 13,616 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Dimensional Fund Advisors LP Makes New $347,000 Investment in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Barclays PLC Boosts Stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
VTYX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Ventyx Biosciences, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Mariner LLC Sells 8,485 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your RightsVTYX - ACCESS Newswire
Ventyx Biosciences Reports Q1 2025 Financial Results - TipRanks
Investors who lost money on Ventyx Biosciences, Inc. (VTYX) should contact Levi & Korsinsky about pending Class ActionVTYX - ACCESS Newswire
Investors who lost money on Ventyx Biosciences, Inc.(VTYX) should contact Levi & Korsinsky about pending Class ActionVTYX - ACCESS Newswire
Lost Money on Ventyx Biosciences, Inc.(VTYX)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Shareholders of Ventyx Biosciences, Inc. Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your RightsVTYX - ACCESS Newswire
Market Resilience: Ventyx Biosciences Inc (VTYX) Finishes Weak at 1.28, Down -5.88 - DWinneX
Ventyx Biosciences, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your RightsVTYX - ACCESS Newswire
Shareholders that lost money on Ventyx Biosciences, Inc.(VTYX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Ventyx Biosciences, Inc. - ACCESS Newswire
Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress - The Manila Times
Ratios Uncovered: Breaking Down Ventyx Biosciences Inc (VTYX)’s Trailing Twelve Months Metrics - DWinneX
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
VTYX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024VTYX - ACCESS Newswire
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
0.84%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):